Effect of midazolam on delirium in critically ill patients: a propensity score analysis

He-Jie Shi¹,²,³, Rui-Xia Yuan¹,²,³, Jun-Zhi Zhang¹,²,³, Jia-Hui Chen¹,²,³ and An-Min Hu¹,²,³

Abstract

Objective: To observe the association between exposure to midazolam within 24 hours prior to delirium assessment and the risk of delirium.

Methods: We performed a systematic cohort study with two sets of cohorts to estimate the relative risks of outcomes among patients administered midazolam within 24 hours prior to delirium assessment. Propensity score matching was performed to generate a balanced 1:1 matched cohort and identify potential prognostic factors. The outcomes included the odds of delirium, mortality, length of intensive care unit stay, length of hospitalization, and odds of being discharged home.

Results: A total of 78,364 patients were included in this study, of whom 22,159 (28.28%) had positive records. Propensity matching successfully balanced covariates for 9348 patients (4674 per group). Compared with no administration of midazolam, midazolam administration was associated with a significantly higher risk of delirium, higher mortality, and a longer intensive care unit stay. Patients treated with midazolam were relatively less likely to be discharged home. There was no significant difference in hospitalization duration.

Conclusions: Midazolam may be an independent risk factor for delirium in critically ill patients.

Keywords
Midazolam, delirium, critical care, propensity score analysis, cohort study, risk factor

Date received: 28 October 2021; accepted: 3 March 2022

¹Department of Anesthesiology, Shenzhen People’s Hospital, Shenzhen, China
²The Second Clinical Medical College, Jinan University, Shenzhen, China
³First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China

Corresponding author:
An-Min Hu, Department of Anesthesiology, Shenzhen People’s Hospital, No.1017 Dongmen Street, Shenzhen, Guangdong 518020, China.
Email: anmin.edu@gmail.com
Introduction

Delirium is a syndrome characterized by the acute onset of cerebral dysfunction with a change or fluctuation in mental status, inattention, and either disorganized thinking or an altered level of consciousness. Delirium in patients over the age of 65 years is estimated to cost more than $164 billion per year in the United States. With the government considering limiting payments for delirium, aggressive efforts are needed to reduce all factors contributing to this condition.

Midazolam is still frequently used for sedation because of its limited effect on hemodynamics and short half-life, despite clinical practice guidelines describing that benzodiazepine use is a modifiable risk factor for delirium in critically ill adults with strong supporting evidence. However, real-world evidence of the relative effectiveness of midazolam and its associations with delirium in critically ill patients is lacking.

Based on the common use of midazolam for the sedation of patients admitted to the intensive care unit (ICU), we performed a retrospective, multicenter, observational cohort study to investigate the relationship between midazolam administration within 24 hours prior to delirium assessment and the incidence of delirium in patients in the ICU and patient-centered outcomes.

Data source

Study data were derived from three electronic databases. The Multiparameter Intelligent Monitoring in Intensive Care (MIMIC) III (version 1.4) Database, Medical Information Mart for Intensive Care (MIMIC) IV (version 0.4) Database, and eICU Collaborative Research Database are maintained by the Laboratory for Computational Physiology at the Massachusetts Institute of Technology.

Study population and stratification

All patient details have been deidentified. The study population included all patients who underwent delirium assessment after admission to the ICU. For patients with multiple positive values, we included only the first episode. If all assessment results were negative, we selected only the first assessment. The variables chosen for each patient were collected only once. Patients who received midazolam or not within 24 hours before the diagnosis of delirium were observed. We performed a cohort study, and patients were enrolled into two cohorts: midazolam and no midazolam.

The inclusion criteria in this study were as follows: (1) for patients with multiple ICU stays, only the first ICU stay was eligible; (2) adults received midazolam at ICU admission; (3) ICU stay ≥24 hours; and (4) delirium assessment.

Outcomes

The primary outcome was the odds ratio (OR) of delirium, and secondary outcomes included hospital mortality, ICU length of stay, hospitalization duration, and discharge destination (home versus elsewhere).
Data analysis

Patient characteristics included age, sex, ethnicity, acute physiology and chronic health evaluation (APACHE) III score, Glasgow Coma Scale, mean blood pressure, respiratory rate, urine volume, hemoglobin, white blood cell count, alanine transaminase, glutamic oxaloacetic transaminase, albumin, blood urea nitrogen, creatinine, lactate, oxygenation index, mechanical ventilation, and hospital characteristics. The APACHE-III scoring system is designed to prospectively predict mortality in individual patients in the ICU.14 Hospital characteristics, including ICU type, number of ICU beds, and teaching status, were defined according to the database.

Descriptive data are presented as the medians (25th to 75th percentiles) for continuous variables and frequencies (%) for categorical variables. Categorical variables were compared between groups using the chi-square test. Unpaired t-tests or Kruskal–Wallis tests were used for continuous variables.

Propensity score generation, stratification by deciles, and 1:1 matching between groups were performed using the R package MatchIt.15 A non-parsimonious regression model was used to produce a propensity score for the group with fewer patients using the patient characteristics described above. For the propensity score analysis (our primary analysis), each patient in the group with fewer patients was matched to their nearest neighbor with a score within 0.001. We chose to match to the third decimal point (a caliper of 0.001) because this value is less than 0.02 standard deviations of the propensity score, which is a commonly suggested range. Estimating the propensity score using a logit model resulted in both reasonable matches and an appropriate overall sample size. An unpaired t-test was used before propensity matching, and a paired t-test was used after matching. The final models included the hospital as a random effect, and all patient characteristics were used to calculate the propensity score. Additionally, multivariable regression modeling, including all patient characteristics used to calculate the propensity score, was performed to confirm these findings (secondary analysis). All analyses were performed using R version 4.0.3 (www.r-project.org).

Results

A total of 46,428 patients in the ICU and 61,051 ICU admissions in the MIMIC-III database v1.4, 50,048 patients in the ICU and 69,619 ICU admissions in the MIMIC-IV database v0.4, and 177,863 patients in the ICU and 626,858 ICU admissions in the eICU Collaborative Research Database were available (Supplementary Table 1). Of these, 621,189 sequential delirium assessment records were available. Finally, 78,364 (28.56%) patients were included in this study. We identified 22,159 (28.28%) patients with positive records. Missing data were imputed with the multivariate imputation using the chain equations (MICE) method.16 The amount of missing data was low.

A total of 4808 patients received midazolam within 24 hours of admission. Before propensity score matching, there were statistically significant differences in age and ethnicity in the stratified analyses between the midazolam and no midazolam groups. Overall, compared with patients in the no midazolam group, patients in the midazolam group were less likely to be women ($P<0.001$) and had a higher APACHE-III score ($P<0.001$). However, patients who received midazolam had higher blood urea nitrogen ($P<0.001$) and white blood cell count ($P<0.001$) values but lower mean blood pressure ($P<0.001$), hemoglobin
(\(P < 0.001\)), alanine transaminase (\(P < 0.001\)), glutamic oxaloacetic transaminase (\(P < 0.001\)), and albumin (\(P < 0.001\)) values than those who did not receive midazolam. Moreover, patients in the midazolam group had higher rates of mechanical ventilation (\(P < 0.001\)) and a higher oxygenation index (\(P < 0.001\)) than those in the no midazolam group (Table 1).

**Propensity-matched analysis**

After propensity matching, 97% of patients in the midazolam group were successfully matched 1:1 with an equal number of patients in the no midazolam group, yielding a total of 4674 patients in each group. Propensity matching eliminated differences between patients and clinical variables and reduced differences in hospital characteristics. After matching, the baseline characteristics were balanced, as shown in Table 1.

In the fully adjusted, propensity score-matched cohorts, patients treated with midazolam exhibited a significant difference in the odds of delirium (OR, 2.54; 95% confidence interval [CI], 2.31–2.79; \(P < 0.001\)) compared with patients who were not treated with midazolam. Moreover, patients who used midazolam had higher odds of mortality (OR, 1.33; 95% CI, 1.17–1.52; \(P < 0.001\)), more ICU days (0.37; 95% CI, 0.29–0.45; \(P < 0.001\)), and lower odds of being discharged home (OR, 0.81; 95% CI, 0.74–0.89; \(P < 0.001\)) than patients who did not use midazolam. However, there were no significant differences in the hospital length of stay between the two groups (Table 2).

**Multivariable analysis**

The entire cohort (78,364 patients) was then analyzed using multivariable regression after adjusting for differences in the patient and hospital characteristics used to calculate the propensity score. This multivariable analysis demonstrated that patients treated with midazolam exhibited significant differences in the odds of delirium (OR, 3.04; 95% CI, 2.83–3.26; \(P < 0.001\)) and mortality rate (OR, 1.30; 95% CI, 1.18–1.43; \(P < 0.001\)) compared with patients who were not treated with midazolam. However, patients treated with midazolam had longer ICU stays (0.54; 95% CI, 0.50–0.57; \(P < 0.001\)) but similar hospital stays (−0.03; 95% CI, −0.30 to 0.23) than patients who were not treated with midazolam. Finally, patients who were not treated with midazolam had an increased likelihood of being discharged home than patients treated with midazolam (0.79; 95% CI, 0.73–0.84; \(P < 0.001\)) (Table 2).

**Discussion**

Using three large databases, MIMIC III v1.4, MIMIC-IV v0.4, and eICU Collaborative Research, we performed a multicenter, observational cohort study to assess outcomes in patients at risk for delirium who were treated with midazolam infusions within 24 hours before delirium diagnoses were defined. We observed that delirium was diagnosed in 28.28% of patients, and patients who used midazolam within 24 hours before diagnosis were more likely to develop delirium. Moreover, our data show that midazolam was associated with multiple detrimental outcomes, including an increased risk of mortality, longer ICU stays, and lower likelihood of being discharged. However, there was no significant association between treatment with midazolam and hospitalization length.

Clinical practice guidelines mention that benzodiazepine use is a modifiable factor, with strong evidence for an association with delirium detected by screening tools.\(^{10}\) Recently, published meta-analyses have demonstrated that midazolam was associated with a significantly higher rate of delirium.\(^{17,18}\) These studies were limited by small sample sizes and limited long-term
| Clinical variable* | Before propensity matching | After propensity matching |
|-------------------|---------------------------|---------------------------|
|                   | Midazolam (N=4808)       | No Midazolam (N=73,556)   |
|                   | SD                       | SD                        |
|                   | P value                  | P value                   |
| Age, No. (%)      |                           |                           |
| 18 to 45 years    | 945 (19.7)               | 9,582 (13)                | 0.261 <0.001 | 1,018 (18.7) | 767 (19.7) | 0.033 0.65 |
| 46 to 65 years    | 1,876 (39)               | 25,641 (34.9)             | 2.164 (39.7) | 1,527 (39.2) |
| 66 to 80 years    | 1,404 (29.2)             | 24,495 (33.3)             | 1,644 (30.1) | 1,073 (27.6) |
| 81 to 89 years    | 458 (9.5)                | 10,342 (14.1)             | 500 (9.2)    | 409 (10.5)   |
| over 89 years     | 125 (2.6)                | 3,496 (4.8)               | 129 (2.4)    | 117 (3)      |
| Women, No. (%)    | 2,002 (41.6)             | 33,697 (45.8)             | 2,206 (40.4) | 1,701 (43.7) | 0.002 0.933 |
| Ethnicity, No. (%)|                           |                           |
| White             | 2,940 (61.1)             | 50,421 (68.5)             | 3,286 (60.2) | 2,488 (63.9) | 0.016 0.964 |
| Black             | 542 (11.3)               | 9,572 (13)                | 596 (10.9)   | 453 (11.6)   |
| Latino            | 173 (3.6)                | 3,253 (4.4)               | 199 (3.6)    | 146 (3.8)    |
| Asian             | 121 (2.5)                | 1,850 (2.5)               | 143 (2.6)    | 98 (2.5)     |
| Other             | 1,032 (21.5)             | 8,460 (11.5)              | 1,231 (22.6) | 708 (18.2)   |
| APACHE-III score  | 51 (36–72)               | 38 (28–52)                | 51 (36–74)   | 47 (34–67)   | 0.035 0.087 |
| Glasgow Coma Scale| 15 (13–15)               | 13.2 (13–15)              | 15 (14–15)   | 14 (13–15)   | 0.003 0.866 |
| Mean blood pressure, mmHg | 80.3 (71.3–91.7) | 85.4 (75.3–93.5) | 0.193 <0.001 | 78.3 (70.3–88.7) | 84.7 (74.7–95.3) | 0.002 0.199 |
| Respiratory rate, beats per minute | 19 (16–23) | 19 (16.5–22) | 0.063 <0.001 | 19 (16–22) | 19.4 (16.5–22.9) | 0.016 0.433 |
| Urine volume, mL/kg/hour | 1.1 (0.7–1.5) | 1.1 (0.7–1.5) | 0.002 0.9 | 1.1 (0.7–1.5) | 1.1 (0.7–1.5) | 0.012 0.553 |
| Hemoglobin, g/dL  | 10.7 (9–11.7)            | 10.9 (9.7–11.8)           | 0.169 <0.001 | 10.5 (9–11.6) | 10.9 (9.3–11.6) | 0.005 0.793 |
| White blood cell, K/µL | 11.6 (8.1–15.2) | 11.3 (8.7–13.7) | 0.086 <0.001 | 12 (8.7–15.9) | 11.1 (8.1–13.8) | 0.009 0.655 |
| Alanine transaminase, IU/L | 679 (23–100.9) | 741 (26–96.8) | 0.095 <0.001 | 683 (22–100.4) | 75.7 (26–104.9) | 0.008 0.696 |
| Glutamic oxaloacetic transaminase, IU/L | 90.6 (33–144.1) | 99.3 (31–136.8) | 0.112 <0.001 | 90 (33–142.8) | 101 (37–147.1) | 0.012 0.566 |
| Albumin, g/dL     | 3.1 (2.8–3.4)            | 3.3 (3–3.5)               | 3.1 (2.8–3.4) | 3.2 (2.9–3.4) | 0.028 0.181 |
| Blood urea nitrogen, mg/dL | 21 (13–34) | 20 (15–29) | 0.093 <0.001 | 20.9 (14–33.6) | 21 (14–31) | 0.015 0.458 |
| Creatinine, mg/dL | 1 (0.7–1.6)              | 1.1 (0.8–1.4)             | 0.029 0.052 | 1 (0.7–1.6)   | 1.1 (0.7–1.5)   | 0.02 0.322 |
| Lactate, mg/dL    | 1.7 (1.3–2.1)            | 1.8 (1.5–2.2)             | 0.019 0.136 | 1.7 (1.3–2.2) | 1.7 (1.4–2.1) | 0.016 0.427 |
| Oxygenation index | 54.7 (50–60.4)           | 51.9 (50.6–57.3)          | 0.717 <0.001 | 53.9 (50–60) | 55.9 (50.8–60.9) | 0.045 0.03 |
| Mechanical ventilation, No. (%) | 3,134 (65.2) | 13,534 (18.4) | 1.077 <0.001 | 3,000 (64.1) | 2,952 (63.1) | 0.021 0.312 |

(continued)
Table 1. Continued.

| Clinical variable | Before propensity matching | After propensity matching | SD# | P value | Before propensity matching | After propensity matching | SD# | P value |
|-------------------|----------------------------|---------------------------|-----|---------|----------------------------|---------------------------|-----|---------|
| ICU type, No. (%) |                            |                           |     |         |                            |                           |     |         |
| SICU              | 227 (4.7)                  | 3,462 (4.7)               | 0.399| <0.001  | 213 (3.9)                  | 230 (5.9)                 | 0.065| 0.02    |
| CCU               | 126 (2.6)                  | 6,678 (9.1)               | 0.508| <0.001  | 112 (2.1)                  | 107 (2.7)                 | 0.073| 0.002   |
| NICU              | 10 (0.2)                   | 3,000 (4.1)               |      |         | 7 (0.1)                    | 5 (0.1)                   |      |         |
| Others            | 4,445 (92.5)               | 60,416 (82.1)             |      |         | 5,123 (93.9)               | 3,551 (91.2)              |      |         |
| Number of beds, No. (%) |                |                           |     |         |                            |                           |     |         |
| <100              | 0 (0)                      | 470 (0.6)                 | 0.508| <0.001  | 0 (0)                      | 0 (0)                     | 0.073| 0.002   |
| 100–249           | 74 (1.5)                   | 5,477 (7.4)               |      |         | 55 (1)                     | 65 (1.7)                  |      |         |
| 250–499           | 85 (1.8)                   | 7,762 (10.6)              |      |         | 55 (1)                     | 87 (2.2)                  |      |         |
| ≥500              | 4,649 (96.7)               | 59,847 (81.4)             |      |         | 5,345 (98)                 | 3,741 (96.1)              |      |         |
| Teaching, No. (%) | 4,586 (95.4)               | 56,129 (76.3)             | 0.569| <0.001  | 5,268 (96.6)               | 3,703 (95.1)              | 0.073| 0.001   |

*Data shown as the mean ± standard deviation, number (percent), or median (interquartile range) as appropriate.

#SD = standardized difference (SD 0.1 represents significant differences in covariables between groups).

APACHE-III score, the acute physiology and chronic health evaluation III score; CCU, cardiac care unit; NICU, neurological intensive care unit; SICU, surgical intensive care unit.
observations. Another propensity score-matched cohort study showed that midazolam-dominant sedation strategies were associated with an increased delirium risk, mortality, length of ICU stay, and hospital days. Unfortunately, they did not test the isolated effects of midazolam and eliminate the influence of midazolam metabolism and clearance, whereas our study did. Additionally, a single-center analysis showed that benzodiazepine administration in an awake patient without delirium was associated with an increased risk of delirium the next day. However, a multicenter systematic comparison of the effectiveness and safety of midazolam within 24 hours prior to delirium assessment in patients in the ICU has been lacking.

There are multiple mechanisms by which midazolam may increase delirium. Midazolam activates γ-aminobutyric acid A (GABA_A) neuronal receptors in the brain, and their activation can alter the levels of numerous neurotransmitters, such as dopamine, serotonin, acetylcholine, norepinephrine, and glutamate, which are believed to be deliriogenic. Midazolam may be involved in the pathogenesis of delirium through overstimulation of the cortical GABA system, thereby reducing corticostriatal glutamatergic tone and ultimately impairing the filtering action of the thalamus, leading to confusion or psychosis. In addition to altering neurotransmitter concentrations, midazolam may generate more central nervous system inhibitory effects at higher doses and impair the quality of sleep via slow-wave sleep suppression, possibly contributing to delirium. Furthermore, midazolam alters sleep patterns and increases the risk of circadian disruption and delirium in humans. We did not pool more risk factors for delirium but presented results from each pre-collected item separately. Our authors independently screened and extracted data using a prespecified data extraction scheme, a process intended to reduce bias during data collection.

Delirium may increase mortality, which is not directly related to midazolam administration. Midazolam use was found to be a risk factor for delirium after liver transplantation in a systematic review and meta-analysis, which also showed that delirium was a mortality risk factor according to the pooled results of ICU mortality. Similarly, a multicenter, retrospective, cohort study by Lonardo et al. demonstrated higher mortality in patients managed with benzodiazepines than in those administered propofol. They postulated that the mortality effect of midazolam might be due to increased rates of delirium and some evidence supports that delirium is associated with substantial morbidity both during and after ICU admission. Each additional day of delirium increases the hazard

|                          | Propensity matched analysis (N=9348) | Multivariable analysis (N=78,364) |
|--------------------------|-------------------------------------|----------------------------------|
|                          | Estimate 95% CI  P value             | Estimate 95% CI  P value         |
| Odds of delirium, OR    | 2.54 2.31 to 2.79 <0.001             | 3.04 2.83 to 3.26 <0.001         |
| Odds of mortality, OR   | 1.33 1.17 to 1.52 <0.001             | 1.30 1.18 to 1.43 <0.001         |
| Difference in ICU days   | 0.37 0.29 to 0.45 <0.001             | 0.54 0.50 to 0.57 <0.001         |
| Difference in hospital days | −0.35 −0.66 to −0.04 0.03   | −0.03 −0.30 to 0.23 0.81         |
| Odds of discharge to home, OR | 0.81 0.74 to 0.89 <0.001 | 0.79 0.73 to 0.84 <0.001         |

OR, odds ratio; CI, confidence interval; ICU, intensive care unit.
of mortality by 10% and increases the likeli-
hood of a poor functional status at 3 and 6 months.\textsuperscript{33–36}

Our study has three strengths. First, this retrospective cohort study included a relatively large population and accurately measured clinical variables in an actual clinical setting in a large number of ICUs. Acknowledging the possibility of confounding, we used propensity score-matched analysis to balance measured pretreatment variables that may influence the effect and impact the outcomes. Second, it is important to use time-dependent multivariable analysis methods given that disease severity, midazolam administration, and delirium occurrence frequently oscillate over the course of the ICU stay. We ensured that medical treatment was provided within 24 hours before the delirium assessment to limit the influence of other confounding factors. Third, this study used data from multiple ICU databases across a range of hospital and ICU settings, which made our results accurately reflect the outcomes observed in an actual clinical practice environment.

Several limitations of this study warrant discussion. First, this is an observational study; thus, causal associations cannot be determined. Second, there were some missing data for multiple confounding variables, and some variables, such as drug doses, target sedation levels, treatment durations, or daily data on sedation levels, could not be effectively merged or compared. Bias may still exist despite the use of propensity score matching and regression modeling to control for a variety of patient and hospital confounders. Third, we could not exclude, measure, or control for the use of intermittent midazolam dosing given on an as-needed basis. We could exclude only patients administered other sedative drugs, such as opioid drugs or propofol, to ensure that they received the same medication. Fourth, our study was a retrospective cohort study based on electronic healthcare records, and the data were generated during routine clinical visits. Because the MIMIC-III data ranged from 2001 to 2015, eICU Collaborative Research data ranged from 2014 to 2015, and MIMIC-IV data ranged from 2018 to 2019, our results were adjusted for the admission period.

Conclusions

Patients who use midazolam within 24 hours before the diagnosis of delirium may be more susceptible to developing delirium, and they may have higher odds of mortality, more ICU days, and lower odds of discharge than those who are not treated with midazolam. Further studies are needed to evaluate the mechanism underlying these differences and validate these findings in other cohorts of patients.

Data availability statement

The three databases used in this research, MIMIC-III, MIMIC IV, and eICU, are available for access, in part or in full, by relevant parties subject to abiding by their usage policies. To facilitate the reproduction of our results, we shall make fully anonymized data available on the figshare from the publication of this manuscript (https://figshare.com/s/6ffde470721a04b7b9ca3). Additionally, interested researchers can contact Mr. Hu by email (anmin.edu@gmail.com) for more detailed information.

Acknowledgements

We are thankful to the Laboratory of Computational Physiology at the Massachusetts Institute of Technology, eICU Research Institute, Boston Medical Center in the United States, and Beth Israel Deaconess Medical Center for providing the data used in this research. We thank the AJE website for editing the article, including correcting errors in grammar, punctuation, and word choice.
Declaration of conflicting interest
The authors declare that they have no competing interests.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This work was funded by the Medical Science and Technology Research Fund of Guangdong Province (A2021058) and Clinical Agent Research Fund of Guangdong Province (2022MZ12). The funding institution of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author contributions
HJS and AMH conceived and designed the study. AMH and HJS acquired the data. HJS, RXY, and AMH analyzed and interpreted the data. HJS and RXY drafted the manuscript. AMH and JZZ critically revised the manuscript for valuable intellectual content. AMH, HJS, and JHC performed the statistical analysis. All authors read and approved the final manuscript.

ORCID iD
An-Min Hu https://orcid.org/0000-0002-6507-6423

Supplemental material
Supplemental material for this article is available online.

References
1. Meagher DJ, Leonard M, Donnelly S, et al. A longitudinal study of motor subtypes in delirium: relationship with other phenomenology, etiology, medication exposure and prognosis. J Psychosom Res 2011; 71: 395–403.
2. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). Jama 2001; 286: 2703–2710.
3. Bergeron N, Dubois MJ, Dumont M, et al. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med 2001; 27: 859–864.
4. Gupta N, De Jonghe J, Schieveld J, et al. Delirium phenomenology: what can we learn from the symptoms of delirium? J Psychosom Res 2008; 65: 215–222.
5. Leslie DL, Marcantonio ER, Zhang Y, et al. One-year health care costs associated with delirium in the elderly population. Arch Intern Med 2008; 168: 27–32.
6. Pronovost PJ, Goeschel CA and Wachter RM. The wisdom and justice of not paying for “preventable complications”. Jama 2008; 299: 2197–2199.
7. Martin J, Franck M, Fischer M, et al. Sedation and analgesia in German intensive care units: how is it done in reality? Results of a patient-based survey of analgesia and sedation. Intensive Care Med 2006; 32: 1137–1142.
8. Rhoney DH and Murry KR. National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med 2003; 18: 139–145.
9. Bucknall TK, Manias E and Presneill JJ. A randomized trial of protocol-directed sedation management for mechanical ventilation in an Australian intensive care unit. Crit Care Med 2008; 36: 1444–1450.
10. Devlin JW, Skrobik Y, Gelinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med 2018; 46: e825–e873.
11. Johnson AE, Pollard TJ, Shen L, et al. Mimic-iii, a freely accessible critical care database. Sci Data 2016; 3: 160035.
12. Johnson A, Bulgarelli L, Pollard T, et al. Mimic-iv (version 0.4). PhysioNet 2020.
13. Pollard TJ, Johnson AEW, Raffa JD, et al. The eICU Collaborative Research Database, a freely available multi-center database for critical care research. Sci Data 2018; 5: 180178.
ill hospitalized adults. *Chest* 1991; 100: 1619–1636.
15. Ho D, Imai K, King G, et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. *Journal of Statistical Software* 2011; 42: 1–28.
16. Van Buuren S and Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. *Journal of statistical software* 2011; 45: 1–67.
17. Cui Y, Li G, Cao R, et al. The effect of perioperative anesthetics for prevention of postoperative delirium on general anesthesia: A network meta-analysis. *J Clin Anesth* 2020; 59: 89–98.
18. Zhou S, Deng F, Zhang J, et al. Incidence and risk factors for postoperative delirium after liver transplantation: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci* 2021; 25: 3246–3253.
19. Casault C, Soo A, Lee CH, et al. Sedation strategy and ICU delirium: a multicentre, population-based propensity score-matched cohort study. *BMJ Open* 2021; 11: e045087.
20. Zaal IJ, Devlin JW, Hazeldag M, et al. Benzodiazepine-associated delirium in critically ill adults. *Intensive Care Med* 2015; 41: 2130–2137.
21. Van Der Mast RC. Delirium: the underlying pathophysiological mechanisms and the need for clinical research. *J Psychosom Res* 1996; 41: 109–113.
22. Van der Mast RC. Pathophysiology of delirium. *Journal of geriatric psychiatry and neurology* 1998; 11: 138–145.
23. Pandharipande P and Ely EW. Sedative and analgesic medications: risk factors for delirium and sleep disturbances in the critically ill. *Crit Care Clin* 2006; 22: 313–327, vii.
24. Gaudreau JD and Gagnon P. Psychotogenic drugs and delirium pathogenesis: the central role of the thalamus. *Med Hypotheses* 2005; 64: 471–475.
25. Weinhouse GL and Watson PL. Sedation and sleep disturbances in the ICU. *Crit Care Clin* 2009; 25: 539–549, ix.
26. Bourne RS and Mills GH. Sleep disruption in critically ill patients–pharmacological considerations. *Anaesthesia* 2004; 59: 374–384.
27. Brainard J, Gobel M, Scott B, et al. Health implications of disrupted circadian rhythms and the potential for daylight as therapy. *Anesthesiology* 2015; 122: 1170–1175.
28. Smith HAB, Gangopadhyay M, Goben CM, et al. Delirium and Benzodiazepines Associated With Prolonged ICU Stay in Critically Ill Infants and Young Children. *Crit Care Med* 2017; 45: 1427–1435.
29. Lonardo NW, Mone MC, Nirula R, et al. Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients. *Am J Respir Crit Care Med* 2014; 189: 1383–1394.
30. McNicoll L, Pisani MA, Zhang Y, et al. Delirium in the intensive care unit: occurrence and clinical course in older patients. *J Am Geriatr Soc* 2003; 51: 591–598.
31. Ely EW, Siegel MD and Inouye SK. Delirium in the intensive care unit: an under-recognized syndrome of organ dysfunction. *Semin Respir Crit Care Med* 2001; 22: 115–126.
32. Pisani MA, Murphy TE, Van Ness PH, et al. Characteristics associated with delirium in older patients in a medical intensive care unit. *Arch Intern Med* 2007; 167: 1629–1634.
33. Pisani MA, Kong SY, Kasl SV, et al. Days of delirium are associated with 1-year mortality in an older intensive care unit population. *Am J Respir Crit Care Med* 2009; 180: 1092–1097.
34. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. *Jama* 2004; 291: 1753–1762.
35. Jackson J, Gordon S, Girard T, et al. Delirium as a risk factor for long term cognitive impairment in mechanically ventilated ICU survivors. *Am J Respir Crit Care Med* 2007; 175: A22.
36. Nelson JE, Tandon N, Mercado AF, et al. Brain dysfunction: another burden for the chronically critically ill. *Arch Intern Med* 2006; 166: 1993–1999.